Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy

Journal of Hepatology

Volumn 65, Issue 6, 2016, Pages 1120-1130

  Weiss, Nicolas ^a   Barbier Saint Hilaire, Pierre ^b   Colsch, Benoit ^b   Isnard, Foucauld ^b   Attala, Suleiman ^b   Schaefer, Augustin ^a   Amador, Maria del Mar ^c   Rudler, Marika ^a   Lamari, Foudil ^a   Sedel, Frédéric ^a   Thabut, Dominique ^a   Junot, Christophe ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Blood brain barrier; Cerebrospinal fluid; Cirrhosis; Hepatic encephalopathy; High resolution mass spectrometry; Liquid chromatography; Metabolomics

Indexed keywords

BILE ACID; GLUTAMIC ACID; GLUTAMINE; NUCLEOSIDE; AMINO ACID; AMMONIA;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CHILD PUGH SCORE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENERGY METABOLISM; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; INTENSIVE CARE UNIT; LIQUID CHROMATOGRAPHY; LIVER CIRRHOSIS; LUMBAR PUNCTURE; MALE; MASS SPECTROMETRY; MEDICAL HISTORY; MENINGITIS; MENINGOENCEPHALITIS; METABOLOMICS; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

AMINO ACIDS; AMMONIA; ENERGY METABOLISM; HEPATIC ENCEPHALOPATHY; HUMANS; METABOLOMICS;

EID: 84994704780     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.07.046     Document Type: Article

References (49)

1. [1] Ferenci, P., Lockwood, A., Mullen, K., Tarter, R., Weissenborn, K., Blei, A.T., Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35 (2002), 716–721.
2. [2] Inserm – Dossiers d'information. La cirrhose. 2012.
3. [3] Garcia-Pagan, J.C., Caca, K., Bureau, C., Laleman, W., Appenrodt, B., Luca, A., et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 362 (2010), 2370–2379.
4. [4] Romero-Gomez, M., Montagnese, S., Jalan, R., Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol 62 (2015), 437–447.
5. [5] Rovira, A., Alonso, J., Cordoba, J., MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol 29 (2008), 1612–1621.
6. [6] Poh, Z., Chang, P.E., A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol, 2012, 2012, 480309.
7. [7] Blei, A.T., Cordoba, J., Hepatic encephalopathy. Am J Gastroenterol 96 (2001), 1968–1976.
8. [8] Ong, J.P., Aggarwal, A., Krieger, D., Easley, K.A., Karafa, M.T., Van, L.F., et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 114 (2003), 188–193.
9. [9] Shawcross, D.L., Shabbir, S.S., Taylor, N.J., Hughes, R.D., Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 51 (2010), 1062–1069.
10. [10] Shawcross, D.L., Wright, G., Olde Damink, S.W., Jalan, R., Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 22 (2007), 125–138.
11. [11] Shawcross, D.L., Davies, N.A., Williams, R., Jalan, R., Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 40 (2004), 247–254.
12. [12] Coltart, I., Tranah, T.H., Shawcross, D.L., Inflammation and hepatic encephalopathy. Arch Biochem Biophys 536 (2013), 189–196.
13. [13] Prakash, R., Mullen, K.D., Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 7 (2010), 515–525.
14. [14] Cascino, A., Cangiano, C., Fiaccadori, F., Ghinelli, F., Merli, M., Pelosi, G., et al. Plasma and cerebrospinal fluid amino acid patterns in hepatic encephalopathy. Dig Dis Sci 27 (1982), 828–832.
15. [15] Watanabe, A., Higashi, T., Shiota, T., Takei, N., Sakata, T., Fujiwara, M., et al. Alterations in neutral amino acid transport across the blood-brain barrier in hepatic failure. Res Exp Med (Berl) 183 (1983), 11–18.
16. [16] Vergara, F., Plum, F., Duffy, T.E., Alpha-ketoglutaramate: increased concentrations in the cerebrospinal fluid of patients in hepatic coma. Science 183 (1974), 81–83.
17. [17] Borg, J., Warter, J.M., Schlienger, J.L., Imler, M., Marescaux, C., Mack, G., Neurotransmitter modifications in human cerebrospinal fluid and serum during hepatic encephalopathy. J Neurol Sci 57 (1982), 343–356.
18. [18] Bron, B., Waldram, R., Silk, D.B., Williams, R., Serum, cerebrospinal fluid, and brain levels of bile acids in patients with fulminant hepatic failure. Gut 18 (1977), 692–696.
19. [19] Nicholson, J.K., Holmes, E., Kinross, J.M., Darzi, A.W., Takats, Z., Lindon, J.C., Metabolic phenotyping in clinical and surgical environments. Nature 491 (2012), 384–392.
20. [20] Child, D.L., Mathews, J.A., Thompson, R.P., Arthritis and primary biliary cirrhosis. Br Med J, 2, 1977, 557.
21. [21] Kamath, P.S., Scoring severity of chronic liver disease. J Gastroenterol Hepatol 17 (2002), S298–S299.
22. [22] Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K.D., et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60 (2014), 715–735.
23. [23] Rama Rao, K.V., Norenberg, M.D., Brain energy metabolism and mitochondrial dysfunction in acute and chronic hepatic encephalopathy. Neurochem Int 60 (2012), 697–706.
24. [24] Mans, A.M., DeJoseph, M.R., Hawkins, R.A., Metabolic abnormalities and grade of encephalopathy in acute hepatic failure. J Neurochem 63 (1994), 1829–1838.
25. [25] Shorey, J., McCandless, D.W., Schenker, S., Cerebral alpha-ketoglutarate in ammonia intoxication. Gastroenterology 53 (1967), 706–711.
26. [26] Muntz, J.A., Hurwitz, J., Effect of potassium and ammonium ions upon glycolysis catalyzed by an extract of rat brain. Arch Biochem Biophys 32 (1951), 124–136.
27. [27] Jones, L.L., McDonald, D.A., Borum, P.R., Acylcarnitines: role in brain. Prog Lipid Res 49 (2010), 61–75.
28. [28] Amodio, P., Angeli, P., Merkel, C., Menon, F., Gatta, A., Plasma carnitine levels in liver cirrhosis: relationship with nutritional status and liver damage. J Clin Chem Clin Biochem 28 (1990), 619–626.
29. [29] Krahenbuhl, S., Reichen, J., Carnitine metabolism in patients with chronic liver disease. Hepatology 25 (1997), 148–153.
30. [30] O'Connor, J.E., Costell, M., New roles of carnitine metabolism in ammonia cytotoxicity. Adv Exp Med Biol 272 (1990), 183–195.
31. [31] Cecere, A., Ciaramella, F., Tancredi, L., Romano, C., Gattoni, A., Efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological test performance in patients with hepatic cirrhosis: results of a randomised trial. Clin Drug Invest 22 (2002), 7–14.
32. [32] Malaguarnera, M., Pistone, G., Elvira, R., Leotta, C., Scarpello, L., Liborio, R., Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 11 (2005), 7197–7202.
33. [33] Jiang, Q., Jiang, G., Shi, K.Q., Cai, H., Wang, Y.X., Zheng, M.H., Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Ann Hepatol 12 (2013), 803–809.
34. [34] Skowronska, M., Albrecht, J., Alterations of blood brain barrier function in hyperammonemia: an overview. Neurotox Res 21 (2012), 236–244.
35. [35] Rackayova, V., Braissant, O., McLin, V.A., Berset, C., Lanz, B., Cudalbu, C., H and P magnetic resonance spectroscopy in a rat model of chronic hepatic encephalopathy: in vivo longitudinal measurements of brain energy metabolism. Metab Brain Dis, 2015.
36. [36] Bachmann, C., Mechanisms of hyperammonemia. Clin Chem Lab Med 40 (2002), 653–662.
37. [37] Jimenez, B., Montoliu, C., MacIntyre, D.A., Serra, M.A., Wassel, A., Jover, M., et al. Serum metabolic signature of minimal hepatic encephalopathy by (1)H-nuclear magnetic resonance. J Proteome Res 9 (2010), 5180–5187.
38. [38] Dabos, K.J., Parkinson, J.A., Sadler, I.H., Plevris, J.N., Hayes, P.C., (1)H nuclear magnetic resonance spectroscopy-based metabonomic study in patients with cirrhosis and hepatic encephalopathy. World J Hepatol 7 (2015), 1701–1707.
39. [39] Gazzin, S., Berengeno, A.L., Strazielle, N., Fazzari, F., Raseni, A., Ostrow, J.D., et al. Modulation of Mrp1 (ABCc1) and Pgp (ABCb1) by bilirubin at the blood-CSF and blood-brain barriers in the Gunn rat. PLoS One, 6, 2011, e16165.
40. [40] Keppler, D., Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol 201 (2011), 299–323.
41. [41] Siniscalchi, A., Mancuso, F., Scornaienghi, D., Ferreri, G., De, S.G., Acute encephalopathy induced by oxcarbazepine and furosemide. Ann Pharmacother 38 (2004), 509–510.
42. [42] Bass, N.M., Mullen, K.D., Sanyal, A., Poordad, F., Neff, G., Leevy, C.B., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362 (2010), 1071–1081.
43. [43] Zimmerman, L., Egestad, B., Jornvall, H., Bergstrom, J., Identification and determination of phenylacetylglutamine, a major nitrogenous metabolite in plasma of uremic patients. Clin Nephrol 32 (1989), 124–128.
44. [44] Hammond, J.W., Potter, M., Truscott, R., Wilcken, B., Gamma-Glutamylglutamine identified in plasma and cerebrospinal fluid from hyperammonaemic patients. Clin Chim Acta 194 (1990), 173–183.
45. [45] Muting, D., Wuzel, H., Bucsis, L., Flasshoff, H.J., Urinary p-hydroxyphenyllactic acid as indicator of hepatic encephalopathy in patients with hepatic cirrhosis. Lancet 2 (1985), 1365–1366.
46. [46] Higashi, T., Impaired metabolism of methionine in severe liver diseases. II. Clinical and experimental studies on role of impaired methionine metabolism in pathogenesis of hepatic encephalopathy. Gastroenterol Jpn 17 (1982), 125–134.
47. [47] Albrecht, J., Zielinska, M., The role of inhibitory amino acidergic neurotransmission in hepatic encephalopathy: a critical overview. Metab Brain Dis 17 (2002), 283–294.
48. [48] Cordoba, J., Gottstein, J., Blei, A.T., Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema. Hepatology 24 (1996), 919–923.
49. [49] Butterworth, R.F., Taurine in hepatic encephalopathy. Adv Exp Med Biol 403 (1996), 601–606.